Global Dermatological Drugs Market to Reach $91.4 Billion by 2035 Driven by Biologics and Targeted Therapies
Dermatological Drugs market was valued at $41.5 billion in 2025 and is projected to reach $91.4 billion by 2035, growing at a CAGR of 8.3% during the forecast period (2026-2035). The global dermatological drugs market is witnessing a significant shift toward biologics and targeted immunotherapies, which have emerged as the dominant drivers of innovation, particularly in the treatment of chronic conditions such as psoriasis, atopic dermatitis, and other autoimmune skin disorders. These advanced therapies, primarily based on monoclonal antibodies and selective cytokine inhibitors, are redefining treatment paradigms by specifically targeting key inflammatory pathways, including interleukin (IL)-17, IL-23, and Janus kinase (JAK) signaling. For instance, in September 2025, Johnson & Johnson received regulatory approval to extend the use of Tremfya for pediatric patients with moderate-to-severe plaque psoriasis. This development reflects the broader shift toward highly selective cytokine inhibition, particularly IL-23 targeting, which has demonstrated strong efficacy and long-term disease control in dermatological conditions.
Browse the full report description of “Dermatological Drugs Market Size, Share & Trends Analysis Report by Drug Class (Corticosteroids, Retinoids, Anti infectives, Calcineurin Inhibitors and Others), by Indication (Acne, Dermatitis, Psoriasis, Skin Cancer, Rosacea, Alopecia, and Others), and by Distribution Channel (Hospital pharmacies, Retail pharmacies, Online Pharmacies, and Dermatology & Aesthetic Clinics), Forecast Period, (2026-2035)” at https://www.omrglobal.com/industry-reports/dermatological-drugs-market
The growing clinical success and improved safety profiles of these agents have contributed to a notable increase in their adoption, with biologic prescriptions experiencing substantial growth in recent years. Unlike conventional systemic therapies that rely on broad immunosuppression, modern biologics offer precision immunomodulation, enabling more effective disease control while minimizing adverse effects. This transition reflects a broader industry movement toward targeted therapeutics that align with evolving patient and physician preferences for safer, long-term treatment options. Furthermore, ongoing research into novel targets such as STAT6 and next-generation JAK inhibitors continues to expand the therapeutic landscape. Pharmaceutical companies are increasingly investing in these advanced modalities to strengthen their pipelines and maintain competitive positioning. The integration of precision medicine approaches is also enhancing treatment personalization, thereby improving clinical outcomes. As a result, biologics and targeted immunotherapies are expected to sustain their leading role in driving market growth. This trend underscores the market’s evolution toward highly specialized and mechanism-driven therapies.
Key Players Driving Innovation in the Dermatological Drugs Market
The major companies operating in the global dermatological drugs market include AbbVie Inc., Galderma S.A., Johnson & Johnson Services, Inc., Pfizer Inc., and Sun Pharmaceutical Industries Ltd., among others. Leading companies in the dermatological drugs market are strengthening their pipelines through extensive research, strategic clinical trials, and the introduction of new therapies. Efforts are centered on developing advanced biologics and precision treatments to meet the growing demand for effective solutions in chronic and challenging skin disorders.
- In January 2026, Almirall announced plans to initiate three new clinical trials in dermatology to advance treatments for high unmet need skin diseases. The studies will explore novel biologics, including monoclonal antibodies and fusion proteins targeting conditions such as hidradenitis suppurativa, alopecia areata, and atopic dermatitis. The company also plans to progress a bispecific antibody for atopic dermatitis into Phase I trials in 2026, expanding its dermatology R&D pipeline.
- In December 2025, Sun Pharmaceutical Industries launched ILUMYA in India for the treatment of moderate-to-severe plaque psoriasis. The biologic therapy targets the IL-23 protein to reduce inflammation and improve long-term skin clearance, offering a more targeted alternative to conventional treatments. Clinical trial results in India demonstrated high efficacy and good tolerability, supporting its use as a new treatment option for psoriasis patients.
Market Coverage
- The market number available for – 2025-2035
- Base year- 2025
- Forecast period- 2026-2035
- Segment Covered-
- Drug Class
- Indication
- Distribution Channel
- Competitive Landscape – AbbVie Inc., Galderma S.A., Johnson & Johnson Services, Inc., Pfizer Inc., and Sun Pharmaceutical Industries Ltd., among others.
Key questions addressed by the report.
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- Who is the leader in the market?
- How are players addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Dendritic Cell Cancer Vaccine Market Report Segment
By Drug Class
- Corticosteroids
- Retinoids
- Anti?infectives
- Calcineurin Inhibitors
- Others
By Indication
- Acne
- Dermatitis
- Psoriasis
- Skin Cancer
- Rosacea
- Alopecia
- Others
By Distribution Channel
- Hospital pharmacies
- Retail pharmacies
- Online Pharmaciese
- Dermatology & Aesthetic Clinics
Global Dendritic Cell Cancer Vaccine Market Report Segment by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
Asia-Pacific
- China
- India
- Japan
- South Korea
- Australia and New Zealand
- ASEAN Economies
- Rest of Asia-Pacific
Rest of the World
- Latin America
- Middle East & Africa
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/dermatological-drugs-market